Merck’s biopharmaceutical branch, EMD Serono, and Pfizer will present clinical activity of treatment with Bavencio (across) multiple tumor types and patient populations at the European Society for Medical Oncology (ESMO) Congress 2019 in Barcelona, Spain.
Chris Boshoff, Pfizer’s Chief Development Officer, Oncology, said that the presentations demonstrate Pfizer’s commitment to identifying the patients most likely to benefit from this immunotherapy as a single agent, or in combination approaches.
Serono’s boss for global R&D said that the immunotherapy era has led to vast progress in the treatment of cancer.
“Yet we know that many patients with advanced or aggressive cancers still need additional treatment options. We are committed to continued research of Bavencion as we seek to further advance treatment options for patients with certain cancers.”